Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$118.93
-1.0%
$119.62
$87.14
$127.57
$6.77B0.95264,032 shs246,809 shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$79.19
-0.1%
$79.70
$54.09
$84.49
$6.89B0.55582,423 shs566,969 shs
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$157.95
-0.5%
$207.48
$123.27
$330.00
$4.69B1.35585,570 shs414,664 shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$65.62
+0.1%
$68.90
$45.50
$84.89
$6.93B1.01913,911 shs616,447 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.00%+0.50%+2.48%-3.04%+35.67%
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.00%-0.16%-1.23%-4.97%+43.87%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
0.00%+2.22%-33.16%-14.24%-46.07%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%+0.34%-10.54%-10.10%+8.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
4.1835 of 5 stars
1.40.03.34.84.02.52.5
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.8747 of 5 stars
3.52.00.00.03.52.53.1
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.9674 of 5 stars
4.34.00.04.84.12.51.9
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
4.5866 of 5 stars
4.52.00.04.52.92.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
2.80
Moderate Buy$124.604.77% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$96.1721.44% Upside
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.69
Moderate Buy$256.5362.41% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.90
Moderate Buy$90.1737.41% Upside

Current Analyst Ratings

Latest ENSG, INSP, HQY, and ITCI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2024
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$250.00 ➝ $255.00
5/8/2024
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$265.00 ➝ $225.00
5/7/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
5/6/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $135.00
4/24/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$120.00
4/23/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/23/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $107.00
4/22/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $90.00
4/22/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $96.00
4/19/2024
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$285.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $90.00
(Data available from 5/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$3.73B1.82$5.69 per share20.91$26.42 per share4.50
HealthEquity, Inc. stock logo
HQY
HealthEquity
$999.59M6.89$3.42 per share23.18$23.72 per share3.34
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$624.80M7.51N/AN/A$19.39 per share8.15
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$512.29M13.52N/AN/A$6.15 per share10.67

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$209.40M$3.8031.3021.781.625.67%17.60%6.33%7/25/2024 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$55.71M$0.64123.7328.381.165.57%6.91%4.41%6/3/2024 (Confirmed)
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
-$21.15M-$0.55N/A195.00N/A-2.38%-2.82%-2.40%8/6/2024 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$1.16N/A70.56N/A-21.57%-18.49%-15.26%8/1/2024 (Estimated)

Latest ENSG, INSP, HQY, and ITCI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2024N/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.6620N/A-$0.6620N/AN/AN/A  
5/7/2024Q1 2024
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
-$0.63-$0.34+$0.29-$0.34$161.41 million$164.01 million      
5/7/2024Q1 2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.31-$0.16+$0.15-$0.16$141.41 million$144.90 million    
5/1/2024Q1 2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$1.19$1.19N/A$1.19$1.01 billion$1.01 billion
3/19/2024Q4 2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.42$0.50+$0.08$0.70$258.56 million$262.39 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$0.240.20%+4.71%6.32%17 Years
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A

Latest ENSG, INSP, HQY, and ITCI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/22/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Quarterly$0.060.19%3/27/20243/31/20244/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.09
1.53
1.53
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.43
4.76
4.76
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/A
7.93
7.25
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
5.12
5.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
96.12%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
94.91%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%

Insider Ownership

CompanyInsider Ownership
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
3.90%
HealthEquity, Inc. stock logo
HQY
HealthEquity
2.20%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.10%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
3.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
35,30056.92 million54.70 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,15087.01 million85.10 millionOptionable
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
1,01129.71 million28.49 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
610105.58 million101.99 millionOptionable

ENSG, INSP, HQY, and ITCI Headlines

Recent News About These Companies

Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up to $67.30

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

The Ensign Group logo

The Ensign Group

NASDAQ:ENSG
The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
HealthEquity logo

HealthEquity

NASDAQ:HQY
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.
Inspire Medical Systems logo

Inspire Medical Systems

NYSE:INSP
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Intra-Cellular Therapies logo

Intra-Cellular Therapies

NASDAQ:ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.